Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

被引：0
|
作者：
Gross-Goupil, M. [1 ]
Kwon, T. G. [2 ]
Eto, M. [3 ]
Ye, D. [4 ]
Miyake, H. [5 ]
Seo, S. I. [6 ]
Byun, S. S. [7 ]
Lee, J. L. [8 ]
Master, V. [9 ]
Jin, J. [10 ]
Debenedetto, R. [11 ]
Linke, R. [12 ]
Casey, M. [13 ]
Rosbrook, B. [14 ]
Frean, M. J. Lechuga [15 ]
Valota, O. [16 ]
Grande, E. [17 ]
Quinn, D. I. [18 ]
机构：
[1] Hop St Andre, Dept Oncol, CHU Bordeaux, Bordeaux, France
[2] Kyungpook Natl Univ, Sch Med, Daegu, South Korea
[3] Kyushu Univ, Dept Clin Med, Fukuoka, Fukuoka, Japan
[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Hamamatsu Univ, Sch Med, Hamamatsu, Shizuoka, Japan
[6] Sungkyunkwan Univ, Dept Urol, Seoul, South Korea
[7] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea
[8] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[9] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA
[10] Peking Univ, Dept Urol, Hosp 1, Beijing, Peoples R China
[11] SFJ Pharmaceut, Clin Dev & Med Affairs, Pleasanton, CA USA
[12] SFJ Pharmaceut Inc, Clin Dev & Med Affairs, Pleasanton, CA USA
[13] Pfizer Inc, Dept Oncol, Collegeville, PA USA
[14] Pfizer Inc, Translat Oncol, La Jolla, CA USA
[15] Pfizer Italia Srl, Dept Oncol, Milan, Italy
[16] Pfizer Srl, Dept Oncol, Milan, Italy
[17] MD Anderson Canc Ctr Ctr Espana, Dept Med Oncol, Madrid, Spain
[18] Univ Southern Calif, Translat & Clin Sci Program, Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
863O
引用
收藏
页码：303 / 303
页数：1
相关论文
共 50 条
  • [41] DISEASE MANAGEMENT COSTS FOR PATIENTS WITH INTERMEDIATE-HIGH OR HIGH-RISK RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY
    Lai, Y.
    Song, Y.
    Zhang, S.
    Bhattacharya, R.
    Carley, C.
    Bensimon, A.
    VALUE IN HEALTH, 2022, 25 (12) : S128 - S128
  • [42] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    Cella, D.
    Escudier, B.
    Rini, B.
    Chen, C.
    Bhattacharyya, H.
    Tarazi, J.
    Rosbrook, B.
    Kim, S.
    Motzer, R.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1571 - 1578
  • [43] Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
    D Cella
    B Escudier
    B Rini
    C Chen
    H Bhattacharyya
    J Tarazi
    B Rosbrook
    S Kim
    R Motzer
    British Journal of Cancer, 2013, 108 : 1571 - 1578
  • [44] A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Noneclear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With Temsirolimus
    Park, Inkeun
    Lee, Se Hoon
    Lee, Jae Lyun
    CLINICAL GENITOURINARY CANCER, 2018, 16 (05) : E997 - E1002
  • [45] Approaches to Treating High Risk and Advanced Renal Cell Carcinoma (RCC): Key Trial Data That Impacts Treatment Decisions in the Clinic
    Chatzkel, Jonathan
    Fishman, Mayer
    Ramnaraign, Brian
    O'Malley, Padraic
    Sonpavde, Guru P.
    RESEARCH AND REPORTS IN UROLOGY, 2024, 16 : 161 - 176
  • [46] Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
    Kaymakcalan, M. D.
    Je, Y.
    Sonpavde, G.
    Galsky, M.
    Nguyen, P. L.
    Heng, D. Y. C.
    Richards, C. J.
    Choueiri, T. K.
    BRITISH JOURNAL OF CANCER, 2013, 108 (12) : 2478 - 2484
  • [47] Characterization of Hemoglobin and Renal Function Trends After Reoperative Partial Nephrectomies in Patients With Recurrent Renal Cell Carcinoma (RCC)
    Antony, Maria
    Gopal, Nikhil
    Blake, Zoe
    Gurram, Sandeep
    Ball, Mark
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 644 - 644
  • [48] Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT).
    Motzer, Robert J.
    Haas, Naomi B.
    Donskov, Frede
    Gross-Goupil, Marine
    Varlamov, Sergei
    Kopyltsov, Evgeny
    Lee, Jae-Lyun
    Melichar, Bohuslav
    Rini, Brian I.
    Choueiri, Toni K.
    Zemanova, Milada
    Wood, Lori A.
    Fahlenkamp, Dirk
    Reaume, Martin Neil
    Stenzl, Arnulf
    Bao, Weichao
    Aimone, Paola
    Doehn, Christian
    Russo, Paul
    Sternberg, Cora N.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
    M D Kaymakcalan
    Y Je
    G Sonpavde
    M Galsky
    P L Nguyen
    D Y C Heng
    C J Richards
    T K Choueiri
    British Journal of Cancer, 2013, 108 : 2478 - 2484
  • [50] AXITINIB VS SORAFENIB FOR ADVANCED RENAL CELL CARCINOMA: PHASE III OVERALL SURVIVAL RESULTS AND ANALYSIS OF PROGNOSTIC FACTORS
    Motzer, R. J.
    Escudier, B.
    Tomczak, P.
    Negrier, S.
    Gore, M. E.
    Tarazi, J.
    Hariharan, S.
    Rosbrook, B.
    Kim, S.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 262 - 262
12345